News Conference News AHA 2025 Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV Michael O'Riordan November 08, 2025
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News ESC 2022 ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention Shelley Wood August 27, 2022
News Conference News AHA 2020 SCAPIS: CTA Finds Silent CAD in 42% of Middle-aged Adults Shelley Wood November 13, 2020
News Conference News AHA 2019 Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial Shelley Wood November 18, 2019
News Conference News VIVA 2019 Clinicians Get Real on Radiation: ‘Don’t Do Dumb Things’ L.A. McKeown November 07, 2019
News Conference News VIVA 2018 Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease L.A. McKeown November 15, 2018
News Conference News ESC 2017 COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease Todd Neale August 27, 2017
News Conference News EAS 2017 Plaque Attack: Options Evolve for Imaging Coronaries and Carotids, but Link With Hard Outcomes Remains Elusive Yael L. Maxwell May 01, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017